PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT o 2.1 Preface o 2.2 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE o Market ecosystem o Market characteristics o Market segmentation analysis PART 04: MARKET SIZING o Market definition o Market sizing 2019 o Market size and forecast 2019-2024 PART 05: FIVE FORCES ANALYSIS o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition PART 06: CUSTOMER LANDSCAPE PART 07: MARKET SEGMENTATION BY INDICATION o Market segmentation by indication o Comparison by indication o Rhinitis - Market size and forecast 2019-2024 o Sinusitis - Market size and forecast 2019-2024 o Otitis media - Market size and forecast 2019-2024 o Tonsillitis - Market size and forecast 2019-2024 o Market opportunity by indication PART 08: GEOGRAPHIC LANDSCAPE o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES o Market drivers o Market challenges PART 11: MARKET TRENDS o Growing awareness among people about ENT disorder treatment o Strategic mergers and acquisitions o Advances in research on allergic disorders PART 12: VENDOR LANDSCAPE o Overview o Landscape disruption o Competitive scenario PART 13: VENDOR ANALYSIS o Vendors covered o Vendor classification o Market positioning of vendors o AbbVie Inc. o ALK-Abelló AS o Bayer AG o Covis Pharma BV o F. Hoffmann-La Roche Ltd. o GlaxoSmithKline Plc o Johnson & Johnson o Merck & Co., Inc. o Pfizer Inc. o Sanofi PART 14: APPENDIX o Research methodology o List of abbreviations o Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Vendor key offerings Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2019 Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions) Exhibit 09: Global market: Year-over-year growth 2020-2024 (%) Exhibit 10: Five forces analysis 2019 Exhibit 11: Five forces analysis 2024 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2019 Exhibit 18: Customer landscape Exhibit 19: Indication - Market share 2019-2024 (%) Exhibit 20: Comparison by indication Exhibit 21: Rhinitis - Market size and forecast 2019-2024 ($ millions) Exhibit 22: Brief description of types of rhinitis Exhibit 23: Rhinitis - Year-over-year growth 2020-2024 (%) Exhibit 24: Sinusitis - Market size and forecast 2019-2024 ($ millions) Exhibit 25: Brief description of types of sinusitis Exhibit 26: Sinusitis - Year-over-year growth 2020-2024 (%) Exhibit 27: Otitis media - Market size and forecast 2019-2024 ($ millions) Exhibit 28: Otitis media - Year-over-year growth 2020-2024 (%) Exhibit 29: Tonsillitis - Market size and forecast 2019-2024 ($ millions) Exhibit 30: Tonsillitis - Year-over-year growth 2020-2024 (%) Exhibit 31: Market opportunity by indication Exhibit 32: Market share by geography 2019-2024 (%) Exhibit 33: Geographic comparison Exhibit 34: North America - Market size and forecast 2019-2024 ($ millions) Exhibit 35: North America - Year-over-year growth 2020-2024 (%) Exhibit 36: Europe - Market size and forecast 2019-2024 ($ millions) Exhibit 37: Europe - Year-over-year growth 2020-2024 (%) Exhibit 38: Asia - Market size and forecast 2019-2024 ($ millions) Exhibit 39: Asia - Year-over-year growth 2020-2024 (%) Exhibit 40: ROW - Market size and forecast 2019-2024 ($ millions) Exhibit 41: ROW - Year-over-year growth 2020-2024 (%) Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Growth of geriatric population 2009-2018 (%) Exhibit 45: Overlapping symptoms of ENT disorders Exhibit 46: Impact of drivers and challenges Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: AbbVie Inc. - Vendor overview Exhibit 53: AbbVie Inc. - Business segments Exhibit 54: AbbVie Inc. - Organizational developments Exhibit 55: AbbVie Inc. - Geographic focus Exhibit 56: AbbVie Inc. - Key offerings Exhibit 57: ALK-Abelló AS - Vendor overview Exhibit 58: ALK-Abelló AS - Business segments Exhibit 59: ALK-Abelló AS - Geographic focus Exhibit 60: ALK-Abelló AS - Key offerings Exhibit 61: Bayer AG - Vendor overview Exhibit 62: Bayer AG - Business segments Exhibit 63: Bayer AG - Organizational developments Exhibit 64: Bayer AG - Geographic focus Exhibit 65: Bayer AG - Segment focus Exhibit 66: Bayer AG - Key offerings Exhibit 67: Covis Pharma BV - Vendor overview Exhibit 68: Covis Pharma BV - Business segments Exhibit 69: Covis Pharma BV - Organizational developments Exhibit 70: Covis Pharma BV - Key offerings Exhibit 71: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 72: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 73: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 74: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 75: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 76: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 77: GlaxoSmithKline Plc - Vendor overview Exhibit 78: GlaxoSmithKline Plc - Business segments Exhibit 79: GlaxoSmithKline Plc - Organizational developments Exhibit 80: GlaxoSmithKline Plc - Geographic focus Exhibit 81: GlaxoSmithKline Plc - Segment focus Exhibit 82: GlaxoSmithKline Plc - Key offerings Exhibit 83: Johnson & Johnson - Vendor overview Exhibit 84: Johnson & Johnson - Business segments Exhibit 85: Johnson & Johnson - Organizational developments Exhibit 86: Johnson & Johnson - Geographic focus Exhibit 87: Johnson & Johnson - Segment focus Exhibit 88: Johnson & Johnson - Key offerings Exhibit 89: Merck & Co. Inc. - Vendor overview Exhibit 90: Merck & Co. Inc. - Business segments Exhibit 91: Merck & Co. Inc. - Organizational developments Exhibit 92: Merck & Co. Inc. - Geographic focus Exhibit 93: Merck & Co. Inc. - Segment focus Exhibit 94: Merck & Co. Inc. - Key offerings Exhibit 95: Pfizer Inc. - Vendor overview Exhibit 96: Pfizer Inc. - Business segments Exhibit 97: Pfizer Inc. - Organizational developments Exhibit 98: Pfizer Inc. - Geographic focus Exhibit 99: Pfizer Inc. - Segment focus Exhibit 100: Pfizer Inc. - Key offerings Exhibit 101: Sanofi - Vendor overview Exhibit 102: Sanofi - Business segments Exhibit 103: Sanofi - Organizational developments Exhibit 104: Sanofi - Geographic focus Exhibit 105: Sanofi - Segment focus Exhibit 106: Sanofi - Key offerings Exhibit 107: Validation techniques employed for market sizing Exhibit 108: Definition of market positioning of vendors

AbbVie Inc., ALK-Abelló AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi.